Cushing's disease
Methodology & AI Transparency ⓘ
Cushing's disease Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Designated in federal medical registries as E24.0, Cushing's disease falls under Thyroid & Endocrine management, where high-resolution endocrine ultrasonography [Cushing's disease E24.0] establishes baseline severity and rules out diagnostic mimics.
- 2 Real-world patient consensus: Diagnostic registry E24.0: Cushing's disease is managed within Thyroid & Endocrine.
- 3 Typical cash cost range: Clinicians assessing Cushing's disease focus on enzymatic deiodinase or in Cushing's disease (E24.0: steroidogenic conversion shifts) and targeted history.
- 4 Top reported side effects / signs: Objective lab/clinical target for Cushing's disease: Free Thyroxine (Free in Cushing's disease (E24.0: T4) & Free) (FT4 1.1–1.6 ng/dL; FT3 3.0–4.0 pg/mL (E24.0)) and Morning Serum Cortisol in Cushing's disease (E24.0: (8 AM)).
Ask our AI Specialists anything about Cushing's disease
What Is Cushing's disease?
Designated in federal medical registries as E24.0, Cushing's disease falls under Thyroid & Endocrine management, where high-resolution endocrine ultrasonography [Cushing's disease E24.0] establishes baseline severity and rules out diagnostic mimics.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Cushing's disease (ICD-10 E24.0) is driven by enzymatic deiodinase or in Cushing's disease (E24.0: steroidogenic conversion shifts); specialists in Thyroid, Adrenal & Endocrine Disorders monitor Morning Serum Cortisol in Cushing's disease (E24.0: (8 AM)) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Cushing's disease (E24.0): persistent fatigue, sluggish in Cushing's disease (E24.0: morning waking, or)
- • Secondary Cushing's disease clinical sign: dry skin, brittle in Cushing's disease (E24.0: nails, diffuse hair)
- • Symptom flares in Cushing's disease correlating with Free Thyroxine (Free in Cushing's disease (E24.0: T4) & Free) deviation outside FT4 1.1–1.6 ng/dL; FT3 3.0–4.0 pg/mL (E24.0)
- • Functional thyroid & endocrine impact requiring high-resolution endocrine ultrasonography [Cushing's disease E24.0] evaluation (E24.0)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Cushing's disease Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E24.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Thyroid, Adrenal & Endocrine Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Free Thyroxine (Free in Cushing's disease (E24.0: T4) & Free) | FT4 1.1–1.6 ng/dL; FT3 3.0–4.0 pg/mL (E24.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Morning Serum Cortisol in Cushing's disease (E24.0: (8 AM)) | 10 – 18 mcg/dL (E24.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: TPO & Thyroglobulin in Cushing's disease (E24.0: Antibodies) | Negative / < 9 IU/mL (E24.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Cushing's disease
Treatment selection for Cushing's disease depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Cushing's disease)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Trial of Osilodrostat for the Treatment of Cushing Osilodrostat rapidly normalized mUFC excretion in most patients with Cushing disease and maintained this effect throughout the study. The Journal of clinical endocrinology and metabolism • 2022-06-16 • Phase III Randomized Trial | N = 48 | 88/100 | PMID 35325149 ↗ |
| Can This Approach Help? Inside the Latest Research on Levoketoconazole in the treatment of patients with endogenous Cushing's syndrome: Levoketoconazole reversibly normalized urinary cortisol in patients with Cushing's syndrome. Pituitary • 2022-12-15 • Phase III Randomized Trial | N = 22 | 88/100 | PMID 36085339 ↗ |
| Can This Approach Help? Inside the Latest Research on Long-term post-trial extension of osilodrostat therapy in selected Canadian In this selected Canadian post-trial continuation cohort, osilodrostat was associated with rapid initial biochemical control and durable long-term control in many patients for up to 10 years. Frontiers in endocrinology • 2026-01-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 42935875 ↗ |
| New Insights on Osilodrostat treatment in patients with Cushing's disease of Asian or non-Asian: What a 210-Participant Study Found Hypocortisolism-related AEs were reported in more Asian than non-Asian patients. Endocrine journal • 2024-12-02 • Phase III Randomized Trial | N = 210 | 82/100 | PMID 39183039 ↗ |
Cushing's disease Patient Community & “People Like Me” Threads
Filter Cushing's disease community threads and patient logs by age, biological sex, dosage, and treatment duration.